Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-05-08
Freyman Thomas C Files AbbVie (ABBV) Form 4 - May 08, 2026
Freyman Thomas C bought 1.1K ABBV shares in this Form 4 filing, reported to the SEC on 2026-05-08.
- Insider
- Freyman Thomas C
- Issuer
- AbbVie Inc. ABBV · NYSE
- Filed
- Period
- 2026-05-08
- Accession
- 0001239126-26-000002
- Source
- Official filing on sec.gov ↗
Transactions (1)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Freyman Thomas C | 2026-05-08 | Buy | 1.1K | $0.00 | $0.00 | Direct |
| Net change | +1.1K | $0.00 | ||||
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Track ABBV insider activity
Get alerted when AbbVie Inc. executives buy or sell their shares.